Back

GOG 240

Improved survival with bevacizumab in advanced cervical cancer

Date of Publication:

February 20, 2014

Pubmed Link:
https://www.ncbi.nlm.nih.gov/pubmed/24552320
Hypothesis:

Does the addition of Bevacizumab improves OS in women with advanced or recurrent cervical cancer?

Control Arm(s):

Cisplatin (50mg/m2) + paclitaxel (135 or 175 mg/m2)

OR

Topotecan (0.75 mg/m2 days 1, 2, 3) + paclitaxel (175 mg/m2)

Experimental Arm(s):
Primary End Point:

OS

Inclusion Criteria:

Metastatic, persistent, or recurrent cervical carcinoma

Exclusion Criteria:

Recurrent cancer eligible for exenteration

Results:

Bev vs. No Bev:
median f/u: 20.8mos

median OS: 17 mos vs. 13.3 mos (SS)

Fatal adverse event: 1.8% vs. 1.8% (NS)

G3 GI and GU fistulas: 6% vs 1% (SS)

G2 or higher HTN: 25% vs 2% (SS)

Febrile neutropenia: 5% vs. 5% (NS)

Thromboembolism:  8% vs 1% (SS)

Conclusions:

Adding Bevacizumab significantly improves OS in women with advanced or recurrent cervical cancer

Reviewer:
Shitanshu Uppal, OTF